drugset / Trial / NCT03841201
Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma
Phase 2
Completed
50 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Bristol-Myers Squibb · collabEisai Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an exploratory, open-label, single arm, multicenter phase II trial for the evaluation of efficacy and feasibility (as determined by safety and tolerability) of immunotherapy with nivolumab in combination with lenvatinib for patients with multinodular, advanced stage hepatocellular carcinoma in first line therapy
Timeline
- Start
- 2019-06-12
- Primary completion
- 2022-10-27
- Completion
- 2023-05-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |